Display options
Share it on

Ann Transl Med. 2019 Dec;7(23):717. doi: 10.21037/atm.2019.12.26.

Comparison of drugs facilitating endoscopy for patients with acute variceal bleeding: a systematic review and network meta-analysis.

Annals of translational medicine

Ziyuan Zou, Xinwen Yan, Huanpeng Lu, Xingshun Qi, Ye Gu, Xun Li, Bin Wu, Xiaolong Qi

Affiliations

  1. CHESS Center, Institute of Portal Hypertension, The First Hospital of Lanzhou University, Lanzhou 730000, China.
  2. The First School of Clinical Medicine, Nanfang Hospital, Southern Medical University, Guangzhou 510515, China.
  3. Liver Cirrhosis Study Group, Department of Gastroenterology, General Hospital of Shenyang Military Area, Shenyang 110840, China.
  4. Department of Gastroenterology, The Sixth Peoples Hospital of Shenyang, Shenyang 110003, China.
  5. Department of Gastroenterology, The Third Affiliated Hospital of Sun Yat-Sen University, Guangzhou 510630, China.

PMID: 32042733 PMCID: PMC6989971 DOI: 10.21037/atm.2019.12.26

Abstract

BACKGROUND: We aimed to compare the efficacy of different drugs facilitating endoscopy in patients with acute variceal bleeding.

METHODS: Databases were searched to identify randomized controlled trials which compared the efficacy of vasoactive drugs (vasopressin, terlipressin, octreotide, somatostatin) with placebo or each other. The primary outcomes were 6-week and 5-day mortality. Secondary outcomes were 5-day rebleeding, control of initial bleeding and adverse events. Pairwise and network meta-analysis were performed.

RESULTS: We identified 14 RCTs involved 2,187 patients. Four drugs had comparable clinical efficacy in all involving outcomes, except for adverse events. However, we do exhibit a superiority when vasopressin (OR, 4.40; 95% CI: 1.04-19.57), terlipressin (OR, 4.58; 95% CI: 1.63-13.63), octreotide (OR, 5.79; 95% CI: 2.41-16.71) and somatostatin (OR, 5.15; 95% CI: 1.40-27.39) were compared to placebo respectively as for initial hemostasis. In addition, only octreotide was more effective than placebo in decreasing 5-day rebleeding (OR, 0.44; 95% CI: 0.22-0.90). Meanwhile, octreotide was shown to have the highest probability ranking the best to improve initial hemostasis (mean rank =1.8) and carries a lowest risk of adverse events (9.1%) and serious adverse events (0.0%) compared to other drugs.

CONCLUSIONS: Balanced with curative effect and tolerability, octreotide may be the preferred vasoactive drug facilitating endoscopy.

2019 Annals of Translational Medicine. All rights reserved.

Keywords: Cirrhosis; endoscopy; hemorrhage; portal hypertension; vasoconstrictor agents

Conflict of interest statement

Conflicts of Interest: The authors have no conflicts of interest to declare.

References

  1. Gastroenterology. 2015 Sep;149(3):660-8.e1 - PubMed
  2. Hepatol Int. 2018 Feb;12(Suppl 1):91-101 - PubMed
  3. BMJ. 2009 Jul 21;339:b2700 - PubMed
  4. Gastroenterology. 2018 May;154(7):1964-1969 - PubMed
  5. Am J Gastroenterol. 1999 Apr;94(4):1077-82 - PubMed
  6. Hepatology. 2007 Sep;46(3):922-38 - PubMed
  7. J Ayub Med Coll Abbottabad. 2005 Jan-Mar;17(1):10-4 - PubMed
  8. Gastroenterology. 2014 Feb;146(2):412-19.e3 - PubMed
  9. Hepatology. 1992 Jun;15(6):1023-30 - PubMed
  10. Hepatol Int. 2018 Feb;12(Suppl 1):1-10 - PubMed
  11. Stat Med. 2010 Mar 30;29(7-8):932-44 - PubMed
  12. N Engl J Med. 2010 Mar 4;362(9):823-32 - PubMed
  13. J Hepatol. 1994 Feb;20(2):206-12 - PubMed
  14. Am J Gastroenterol. 2012 Dec;107(12):1872-8 - PubMed
  15. J Hepatol. 2015 Sep;63(3):743-52 - PubMed
  16. Am J Gastroenterol. 2000 Mar;95(3):768-71 - PubMed
  17. Scand J Gastroenterol. 1990 Jun;25(6):622-30 - PubMed
  18. Aliment Pharmacol Ther. 2007 Dec;26(11-12):1479-87 - PubMed
  19. Control Clin Trials. 1986 Sep;7(3):177-88 - PubMed
  20. J Hepatol. 2002 Apr;36(4):507-12 - PubMed
  21. J Hepatol. 1992 May;15(1-2):256-61 - PubMed
  22. Med Decis Making. 2013 Jul;33(5):641-56 - PubMed
  23. Expert Opin Drug Saf. 2009 Nov;8(6):755-68 - PubMed
  24. Am J Gastroenterol. 2009 Mar;104(3):617-23 - PubMed
  25. Res Synth Methods. 2013 Dec;4(4):291-323 - PubMed
  26. Lancet. 1997 Nov 22;350(9090):1495-9 - PubMed
  27. Gut. 2019 May;68(5):844-853 - PubMed
  28. Gastroenterology. 2015 Sep;149(3):528-31 - PubMed
  29. J Hepatol. 2002 Feb;36(2):163-8 - PubMed
  30. Lancet. 1982 Jul 10;2(8289):66-8 - PubMed
  31. Hepatology. 2020 Feb;71(2):600-610 - PubMed
  32. Korean J Intern Med. 2003 Sep;18(3):161-6 - PubMed
  33. Hepatology. 2002 Mar;35(3):609-15 - PubMed
  34. Clin Investig. 1994 Sep;72(9):653-9 - PubMed
  35. Hepatol Int. 2018 Feb;12(Suppl 1):81-90 - PubMed
  36. Hepatology. 1986 Jan-Feb;6(1):112-5 - PubMed
  37. J Clin Epidemiol. 2011 Feb;64(2):163-71 - PubMed
  38. Hepatology. 1997 May;25(5):1101-4 - PubMed
  39. BMJ. 1997 Sep 13;315(7109):629-34 - PubMed
  40. J Clin Exp Hepatol. 2015 Sep;5(3):204-12 - PubMed
  41. Aliment Pharmacol Ther. 2012 Apr;35(8):904-12 - PubMed
  42. J Hepatol. 1992 Nov;16(3):320-5 - PubMed
  43. N Engl J Med. 1996 Jan 25;334(4):246-54 - PubMed
  44. Hepatology. 2014 Sep;60(3):954-63 - PubMed
  45. J Hepatol. 2005 Jul;43(1):167-76 - PubMed
  46. Hepatol Int. 2018 Feb;12(Suppl 1):68-80 - PubMed
  47. J Hepatol. 2006 Oct;45(4):560-7 - PubMed
  48. BMJ. 2011 Oct 18;343:d5928 - PubMed
  49. N Engl J Med. 1995 Aug 31;333(9):555-60 - PubMed
  50. BMJ. 2003 Sep 6;327(7414):557-60 - PubMed
  51. Gastroenterology. 2001 Mar;120(4):975-83 - PubMed

Publication Types